214 related articles for article (PubMed ID: 37704591)
21. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
22. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
[TBL] [Abstract][Full Text] [Related]
23. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
[TBL] [Abstract][Full Text] [Related]
24. Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.
Jane EP; Premkumar DR; Cavaleri JM; Sutera PA; Rajasekar T; Pollack IF
J Pharmacol Exp Ther; 2016 Feb; 356(2):354-65. PubMed ID: 26585571
[TBL] [Abstract][Full Text] [Related]
25. Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations.
Henz K; Al-Zebeeby A; Basoglu M; Fulda S; Cohen GM; Varadarajan S; Vogler M
Biol Chem; 2019 Jan; 400(2):181-185. PubMed ID: 29924730
[TBL] [Abstract][Full Text] [Related]
26. NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.
Daressy F; Séguy L; Favre L; Corvaisier S; Apel C; Groo AC; Litaudon M; Dumontet V; Malzert-Fréon A; Desrat S; Roussi F; Robert A; Wiels J
Biomed Pharmacother; 2022 Oct; 154():113546. PubMed ID: 35988426
[TBL] [Abstract][Full Text] [Related]
27. Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL.
Seyfried F; Stirnweiß FU; Niedermayer A; Enzenmüller S; Hörl RL; Münch V; Köhrer S; Debatin KM; Meyer LH
Leukemia; 2022 Apr; 36(4):901-912. PubMed ID: 35031695
[TBL] [Abstract][Full Text] [Related]
28. BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells.
Moujalled D; Southon AG; Saleh E; Brinkmann K; Ke F; Iliopoulos M; Cross RS; Jenkins MR; Nhu D; Wang Z; Shi MX; Kluck RM; Lessene G; Grabow S; Bush AI; Strasser A
Cell Death Differ; 2022 Jul; 29(7):1335-1348. PubMed ID: 35332309
[TBL] [Abstract][Full Text] [Related]
29. Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines.
Lian BSX; Yek AEH; Shuvas H; Abdul Rahman SF; Muniandy K; Mohana-Kumaran N
BMC Res Notes; 2018 Mar; 11(1):197. PubMed ID: 29580266
[TBL] [Abstract][Full Text] [Related]
30. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
31. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
Eichhorn JM; Alford SE; Sakurikar N; Chambers TC
Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425
[TBL] [Abstract][Full Text] [Related]
32. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.
Wang B; Ni Z; Dai X; Qin L; Li X; Xu L; Lian J; He F
Mol Cancer; 2014 Apr; 13():98. PubMed ID: 24779770
[TBL] [Abstract][Full Text] [Related]
33. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition.
Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z
Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561
[TBL] [Abstract][Full Text] [Related]
35. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
Touzeau C; Dousset C; Bodet L; Gomez-Bougie P; Bonnaud S; Moreau A; Moreau P; Pellat-Deceunynck C; Amiot M; Le Gouill S
Clin Cancer Res; 2011 Sep; 17(18):5973-81. PubMed ID: 21821698
[TBL] [Abstract][Full Text] [Related]
36. The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.
Cao X; Yap JL; Newell-Rogers MK; Peddaboina C; Jiang W; Papaconstantinou HT; Jupitor D; Rai A; Jung KY; Tubin RP; Yu W; Vanommeslaeghe K; Wilder PT; MacKerell AD; Fletcher S; Smythe RW
Mol Cancer; 2013 May; 12(1):42. PubMed ID: 23680104
[TBL] [Abstract][Full Text] [Related]
37. Bcl-2 family inhibitors sensitize human cancer models to therapy.
Valentini E; Di Martile M; Brignone M; Di Caprio M; Manni I; Chiappa M; Sergio I; Chiacchiarini M; Bazzichetto C; Conciatori F; D'Aguanno S; D'Angelo C; Ragno R; Russillo M; Colotti G; Marchesi F; Bellone ML; Dal Piaz F; Felli MP; Damia G; Del Bufalo D
Cell Death Dis; 2023 Jul; 14(7):441. PubMed ID: 37460459
[TBL] [Abstract][Full Text] [Related]
38. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
Zhou L; Zhang Y; Sampath D; Leverson J; Dai Y; Kmieciak M; Nguyen M; Orlowski RZ; Grant S
Br J Cancer; 2018 Feb; 118(3):388-397. PubMed ID: 29241222
[TBL] [Abstract][Full Text] [Related]
39. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
[TBL] [Abstract][Full Text] [Related]
40. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
